Hexter Joshua sold $135K of ORMP
Hexter Joshua (COO & CBO) sold 30,000 shares of ORAMED PHARMACEUTICALS INC. (ORMP) at $4.51 ($0.14M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds a data point for analysts tracking insider sentiment at Oramed Pharmaceuticals.
Market read
A modest insider sell by a senior executive; likely limited price impact but worth noting for short‑term traders.
What to watch
The insider retains a large stake (over 1.3 million shares) and the sale size is modest relative to float.
Background
SEC Form 4 filings disclose insider transactions; investors monitor them for potential signals.
Ticker impact
Form 4 shows COO Joshua Hexter sold 30,000 shares for $135,330 via a 10b5‑1 plan.
likely pressure as the market prices in the insider sell.
The sale is a direct, disclosed transaction by a C‑suite officer, indicating potential downside sentiment.
Market effects
Minimal impact on the broader pharma sector; isolated insider activity.
No regional effect; company is US‑listed.
Low; the transaction is company‑specific.
Counterpoint
The sale could be routine portfolio rebalancing under a 10b5‑1 plan, not a negative signal.
Key entities
- CompanyOramed Pharmaceuticals Inc.
US‑listed biopharma company (ticker ORMP).
- IndividualJoshua Hexter
Chief Operating Officer & Chief Business Officer of Oramed.